Inathibitisha ...
Imetafsiriwa kiotomatiki. Dozi na tahadhari: angalia toleo asili la Kiingereza. Soma kwa Kiingereza
Nyumbani / Registered in Nigeria / Myospaz Tablet

Myospaz Tablet

NAFDAC Reg. No. B4-3633 · Drug

Registered with NAFDAC. Registration activeAs of 31 October 2026 · synced automatically from official sources.
Product
Myospaz Tablet
NAFDAC number
B4-3633
Active ingredient
Chlorzoxazone; Paracetamol
Strength
250 mg; 500 mg
Form
Tablet
Pack size
10 x 10's (in blisters)
Manufacturer
Not listed
Applicant (holder)
Phillips Pharmaceuticals (Nigeria) Limited
Approved
26 Apr 2023
Status
Active View on NAFDAC ↗
Registration valid to
25 Apr 2028
WHO alerts
None found
Community reports
None
Times checked
0

About the medicine: Chlorzoxazone: uses, dosage and brands worldwide

What we found

  • Myospaz Tablet is on the NAFDAC register with an active registration (B4-3633). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Myospaz Tablet

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

INDICATIONS Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.

How to take it and how often
  • Usual Adult Dosage One tablet three or four times daily
  • If adequate response is not obtained with this dose, it may be increased to one and one-half tablets (750 mg) three or four times daily
  • As improvement occurs dosage can usually be reduced
Talk to a doctor first if

Chlorzoxazone is contraindicated in patients with known intolerance to the drug.

Warnings

Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. …

Possible side effects

Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance. …

If you take too much

Symptoms Initially, gastrointestinal disturbances such as nausea, vomiting, or diarrhea together with drowsiness, dizziness, lightheadedness or headache may occur. Early in the course there may be malaise or sluggishness followed by marked loss of muscle tone, making voluntary movement impossible. The deep tendon reflexes may be decreased or absent. The sensorium remains intact, and there is no peripheral loss of sensation. Respiratory depression may occur with rapid, irregular respiration and intercostal and substernal retraction. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-03-01.

Label for chlorzoxazone and paracetamol, the active ingredient registered with NAFDAC.

Check your pack of Myospaz Tablet

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Myospaz Tablet

What is in Myospaz Tablet?

Myospaz Tablet contains Chlorzoxazone; Paracetamol (250 mg; 500 mg), as tablet, according to its NAFDAC registration record.

Is Myospaz Tablet registered with NAFDAC?

Yes. Myospaz Tablet is listed on the NAFDAC register under registration number B4-3633, and its registration is active as of 31 October 2026.

Has Myospaz Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Myospaz Tablet in our automatically synced alert list.

How can I check that my pack of Myospaz Tablet is genuine?

Run a free authenticity scan with the NAFDAC number B4-3633, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Myospaz Tablet?

Follow your prescription or the leaflet in your pack. The official label says: Usual Adult Dosage One tablet three or four times daily. If adequate response is not obtained with this dose, it may be increased to one and one-half tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.…

What is Myospaz Tablet used for?

INDICATIONS Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man. (Summarised from the official U.S. FDA label for chlorzoxazone and paracetamol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Myospaz Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.